Dr. Reddy's Laboratories to Acquire Nimbus Health GmbH

Takeda Acquires Nimbus Therapeutics' TYK2 Program Subsidiary (Nimbus Lakshmi)

February 8, 2023

Pharmaceuticals

Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.

Dr. Reddy's to Acquire Haleon's Nicotinell Global NRT Portfolio (Outside the United States)

June 26, 2024

Healthcare Services

Dr. Reddy’s Laboratories SA has signed a definitive agreement to purchase Haleon’s Haleon group company Northstar Switzerland SARL to acquire Haleon’s global Nicotinell nicotine replacement therapy (NRT) brand portfolio outside the United States. The deal includes Nicotinell plus local leading brand names (Nicabate, Habitrol, Thrive) and applicable pipeline products, with about GBP 217 million revenue reported for the portfolio in CY23.

Dr. Reddy's Acquires MenoLabs Women’s Supplement Brand from Amyris

January 5, 2024

Consumer Products

Dr. Reddy's Laboratories has acquired the MenoLabs dietary supplement portfolio and accompanying MenoLife health tracker app from Amyris as part of Amyris' Chapter 11 asset sale, winning the assets in an auction for $3.0 million. The acquisition adds seven branded menopause- and healthy-aging-focused supplements sold primarily via DTC e-commerce and marketplaces to Dr. Reddy's U.S. self-care and wellness portfolio to accelerate growth in women's nutritional and wellness markets.

Organigram Global Acquires Sanity Group GmbH

February 18, 2026

Healthcare Services

Organigram Global Inc. entered into a definitive agreement to acquire all of the issued and outstanding shares of Berlin-based Sanity Group GmbH not currently owned by Organigram. The deal consideration is €113.4 million upfront (including €80.0 million cash and €33.4 million in Organigram shares) plus an earnout of up to €113.8 million tied to Sanity’s financial performance.

Bregal Unternehmerkapital Acquires Majority Stake in medavis GmbH

September 26, 2022

Software

Bregal Unternehmerkapital has taken a majority stake in medavis GmbH, a Karlsruhe-based provider of radiology information systems (RIS) with roughly 20% market share in the DACH region. The two founders, Jörg Dittrich and Elmar Kußmaul, retained significant stakes; Bregal plans to support geographic expansion, product development and extension into adjacent healthcare IT areas.

AbbVie Acquires Nimble Therapeutics in $200 Million Deal

January 23, 2025

Biotechnology

AbbVie announced and later completed the acquisition of Nimble Therapeutics for $200 million in cash at closing, plus interim funding and potential development milestone payments to Nimble shareholders. The deal adds Nimble’s preclinical oral peptide IL23R inhibitor for psoriasis/IBD and its proprietary peptide synthesis, screening, and optimization platform to strengthen AbbVie’s immunology pipeline and R&D capabilities.